Article Text

Download PDFPDF

618 Outcomes of pediatric lupus care delivery in an electronic health record-based pediatric lupus registry
  1. Joyce C Chang1,2,
  2. Shreya A Varghese3 and
  3. Jon M Burnham1
  1. 1Division of Rheumatology, Children’s Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA, USA
  2. 2Division of Immunology, Boston Children’s Hospital and Harvard Medical School, Boston, MA, USA
  3. 3Department of Biomedical and Health Informatics, Children’s Hospital of Philadelphia, Philadelphia, PA, USA


Background There is a need to identify strategies to improve outcomes of children with pediatric-onset systemic lupus erythematosus (pSLE) and related conditions. Current data collection methods commonly employed for research and quality improvement efforts are labor intensive and frequently unsustainable. We describe the use of an autopopulating EHR-based pSLE registry to measure outcomes before and after a Maintenance of Certification (MOC) activity to improve high-quality care delivery.

Data source We extracted data from our EHR-based pSLE research registry from Dec 2018 – July 2022. In November 2018, we implemented electronic health record (EHR) tools at our center to standardize documentation of pSLE clinical characteristics, medication instructions, disease activity, disease damage and target assessments, which autopopulate a quality improvement dashboard and the pSLE research registry. The research registry additionally interfaces with an EHR-based steroid registry and billing data on hospital and rheumatology visit encounters in real-time.

Setting Coinciding with the development of EHR-based tools for pSLE, our center established a Lupus Program in 2018 with input from providers, foundation leaders, patients and families. As of May 2019, programmatic components included a dedicated lupus social worker and a multidisciplinary lupus nephritis clinic with social work support and a psychologist. In order to ensure delivery of high quality care across rheumatology, we began an MOC activity in July 2020 to improve performance on metrics in the previously published pediatric Lupus Care Index (pLUCI). Components included a population management strategy, self-directed evaluation for individual providers, and goal-setting activities.

Measures Primary outcomes included timely follow-up care (defined as <120 days between clinic visits), pneumococcal vaccination rates, and use of steroid-sparing agents. We used modified (robust) Poisson models to estimate the relative probability of each outcome before and after the MOC activity, adjusted for time, patient-level factors (sex, race and ethnicity, social vulnerability index [SVI], major organ manifestations), visit-level factors (age, disease duration, disease activity, prednisone use, and DMARD use), as well as within-subject random effects.

Results Of 133 pSLE or mixed connective tissue disease cases in the EHR-based Registry, 128 had both patient- level and visit-level data forms entered by providers. 110 of these patients had at least two outpatient rheumatology visits during the observation period and were included in this study, 74 of which had follow-up that extended through both pre- and post-MOC periods. There was a median of 7 visits per subject [4-10], comprising a total of 830 outpatient rheumatology visits. Demographic and clinical characteristics at the index visit in both pre- and post-MOC periods are shown in table 1.

The standardized EHR documentation tool was used in 79% of visits pre-MOC and 87% of visits after MOC activities. Both SLEDAI scores and medication data were captured from 76% of pre-MOC visits and 80% of visits after MOC. There was no statistically significant difference in the probability of timely follow-up post-MOC vs. pre-MOC in adjusted models (65% vs. 59%, adjusted RR 1.09, 95% CI [0.93- 1.28]). Hispanic ethnicity, shorter disease duration, higher disease activity, and any DMARD use at the preceding visit were associated with a higher likelihood of timely follow-up (table 2). Of note, Black race and higher SVI were not associated with a lower likelihood of timely follow-up during the observation period, which spanned introduction of a dedicated social worker, the multidisciplinary lupus nephritis clinic, and the COVID-19 pandemic. Among 35 patients with lupus nephritis, Asian race, Black race, Hispanic ethnicity, and higher SVI were all associated with a higher likelihood of timely follow-up. Timely follow-up was achieved 73% of the time in the 20 nephritis patients followed in the multidisciplinary clinic vs. 63% in 15 lupus nephritis patients followed in regular rheumatology clinic, albeit this difference did not reach statistical significance (adjusted RR 1.15 [0.88-1.50]).

On average, pneumococcal vaccination was high (up to date at 84% of visits) and increased over time during the observation period (adjusted RR 1.005 per month, [1.001 – 1.009]), but there was no significant difference pre- vs. post MOC. For lupus nephritis patients, pneumococcal vaccination status was up to date for 98% of visits in the multidisciplinary clinic compared to 90% of visits in rheumatology clinic, albeit not statistically significant (adjusted RR 1.09 [0.91 – 1.30]). There were no significant changes in use of a steroid-sparing agent over time or pre- vs. post MOC.

Conclusions Uptake of pSLE-specific EHR documentation tools was high in the context of a MOC activity to improve high quality pSLE care. While there was no significant change in timely follow-up associated with the MOC activity period, there were also no significant disparities by race or social vulnerability during the observation period, coinciding with a new multidisciplinary lupus program with dedicated social work and psychology support, as well as the COVID-19 pandemic. EHR-based pediatric lupus registries using standardized clinical documentation enables evaluation of longitudinal disease and care delivery outcomes without manual review of medical records and could facilitate learning health networks and health equity research.

Acknowledgements This work was supported by an Investigator-sponsored research grant from GlaxoSmithKline [J.B. and J.C]

Abstract 618 Table 1

Baseline Characteristics at index visit before and after start of MOC

Abstract 618 Table 2

Factors associated with timely outpatient rheumatology follow-up

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: .

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.